Cytosorbents (NASDAQ:CTSO – Get Free Report) and Glaukos (NYSE:GKOS – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.
Volatility & Risk
Cytosorbents has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and price targets for Cytosorbents and Glaukos, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cytosorbents | 0 | 1 | 2 | 1 | 3.00 |
| Glaukos | 1 | 0 | 11 | 1 | 2.92 |
Valuation & Earnings
This table compares Cytosorbents and Glaukos”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cytosorbents | $33.79 million | 1.62 | -$28.51 million | ($0.36) | -2.78 |
| Glaukos | $383.48 million | 15.04 | -$134.66 million | ($2.87) | -35.53 |
Cytosorbents has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cytosorbents and Glaukos’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cytosorbents | -49.47% | -118.54% | -42.31% |
| Glaukos | -39.04% | -16.53% | -10.61% |
Institutional & Insider Ownership
32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 6.6% of Cytosorbents shares are owned by insiders. Comparatively, 6.4% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Glaukos beats Cytosorbents on 8 of the 14 factors compared between the two stocks.
About Cytosorbents
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
About Glaukos
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.
